John A. Steinharter

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

24h-index6.0kcitations145works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(86), Cancer Diagnosis and Treatment(53), Systemic Sclerosis and Related Diseases(52), Renal cell carcinoma treatment(41), Bladder and Urothelial Cancer Treatments(18)

Publications145 total

Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability
Cell Reports·2026Open Access
Precision in Liver Surgery: A Comparative Analysis of Volumetry Techniques
Annals of Surgical Oncology·2025
Assessing future liver remnant prior to hepatectomy: comparison of measured and estimated techniques
HPB·2025
The association of chemotherapy-induced peripheral neuropathy with reduced executive function in chemotherapy-treated cancer survivors: A cross-sectional study
Journal of Geriatric Oncology·2024· 8 citedOpen Access
Executive function is associated with balance and falls in older cancer survivors treated with chemotherapy: A cross-sectional study
Journal of Geriatric Oncology·2023· 13 citedOpen Access
Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma
The Oncologist·2023Open Access
Figure S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S7 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Table S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S4 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Toni K. Choueiri(42), Ziad Bakouny(30), Bradley A. McGregor(25), Lauren C. Harshman(20), Pier Vitale Nuzzo(19), Wanling Xie(19), David A. Braun(18), Sabina Signoretti(18), Eliezer M. Van Allen(17), Gabrielle Bouchard(16), Sarah Abou Alaiwi(15), Xiao X. Wei(15), Ronan Flippot(14), Amin H. Nassar(13), David F. McDermott(12), Rana R. McKay(11), Gwo‐Shu Mary Lee(11), Abdallah Flaifel(11), Laure Hirsch(10), Aly‐Khan A. Lalani(10)